Rick Doblin: Developing Psychedelics Into Prescription Medicines

Rick Doblin, Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS), outlines the organization's long-term strategy for obtaining FDA approval for psychedelic-assisted therapies. The presentation focuses on MDMA-assisted psychotherapy for Posttraumatic Stress Disorder (PTSD) as a primary clinical objective. Highlighting the necessity for robust clinical research over political activism, Doblin discusses ongoing efforts to conduct multi-site clinical trials that meet rigorous scientific standards to ensure safety and therapeutic efficacy. The discussion highlights the importance of standardized protocols for therapy sessions and training for medical professionals. Doblin explains that therapeutic success relies heavily on a strong therapeutic alliance and the ability to process trauma safely. By moving toward prescription medicine status, these efforts aim to provide legitimate relief for populations that haven't responded to conventional treatments.